Open Access

Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer

  • Authors:
    • Manuel Nolasco‑Quiroga
    • Marisol Rosas‑Díaz
    • José Moreno
    • Ricardo Godínez‑Aguilar
    • María José López‑Ibarra
    • Patricia Piña‑Sánchez
    • Isabel Alvarado‑Cabrero
    • Gerardo Vázquez‑Gómez
    • Leticia Rocha‑Zavaleta
    • Diego Arenas‑Aranda
    • Fabio Salamanca‑Gómez
  • View Affiliations

  • Published online on: March 15, 2019     https://doi.org/10.3892/ol.2019.10147
  • Pages: 4779-4786
  • Copyright: © Nolasco‑Quiroga et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Focal adhesion kinase (FAK) is a non‑receptor tyrosine kinase that is expressed in most human cell types (example: Epithelial cells, fibroblasts and endothelial), it serves a key role in the control of cell survival, proliferation and motility. The abnormal expression of FAK has been associated with poor prognosis in cancer, including ovarian cancer. However, although FAK isoforms with specific molecular and functional properties have been characterized, there are a limited number of published studies that examine FAK isoforms in ovarian cancer. The aim of the present study was to analyze the expression level of FAK and its isoforms in ovarian cancer. The expression of FAK kinase and focal adhesion targeting (FAT) domains was determined with immunohistochemistry in healthy ovary, and serous and mucinous cystadenoma, borderline tumor and carcinoma samples. Additionally, the expression of FAK and its isoforms were investigated in three ovarian cancer‑derived cell lines with western blotting and reverse transcription‑semi‑quantitative polymerase chain reaction. An increased expression of FAK kinase domain was determined in serous tumor samples and was associated with advancement of the lesion. FAK kinase domain expression was moderate‑to‑low in mucinous tumor samples. The expression of the FAK FAT domain in tumor samples was reduced, compared with healthy ovary samples; however, the FAT domain was localized to the cellular nucleus. Expression of alternative transcripts FAK0, FAK28,6 and FAK28 was determined in all three cell lines investigated. In conclusion, FAK kinase and FAT domains are differentially expressed among ovarian tumor types. These results indicated the presence of at least two isoforms of FAK (FAK and the putative FAK‑related non‑kinase) in tumor tissue, which is supported by the cells producing at least three FAK alternative transcripts. These results may support the use of FAK and its isoforms as biomarkers for ovarian cancer.
View Figures
View References

Related Articles

Journal Cover

June 2019
Volume 17 Issue 6

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
APA
Nolasco‑Quiroga, M., Rosas‑Díaz, M., Moreno, J., Godínez‑Aguilar, R., López‑Ibarra, M.J., Piña‑Sánchez, P. ... Salamanca‑Gómez, F. (2019). Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer. Oncology Letters, 17, 4779-4786. https://doi.org/10.3892/ol.2019.10147
MLA
Nolasco‑Quiroga, M., Rosas‑Díaz, M., Moreno, J., Godínez‑Aguilar, R., López‑Ibarra, M. J., Piña‑Sánchez, P., Alvarado‑Cabrero, I., Vázquez‑Gómez, G., Rocha‑Zavaleta, L., Arenas‑Aranda, D., Salamanca‑Gómez, F."Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer". Oncology Letters 17.6 (2019): 4779-4786.
Chicago
Nolasco‑Quiroga, M., Rosas‑Díaz, M., Moreno, J., Godínez‑Aguilar, R., López‑Ibarra, M. J., Piña‑Sánchez, P., Alvarado‑Cabrero, I., Vázquez‑Gómez, G., Rocha‑Zavaleta, L., Arenas‑Aranda, D., Salamanca‑Gómez, F."Increased expression of FAK isoforms as potential cancer biomarkers in ovarian cancer". Oncology Letters 17, no. 6 (2019): 4779-4786. https://doi.org/10.3892/ol.2019.10147